Diabetic nephropathy and retinopathy, two important microvascular complications of diabetes, are the main causes of morbidity and mortality among diabetic patients ([@B1]). Diabetic nephropathy is the most common cause of chronic kidney failure and end-stage renal disease, whereas diabetic retinopathy is the leading cause of blindness in the adults ([@B2],[@B3]). With the significant rise in the prevalence of diabetes, the increase of patients suffering from diabetic microvascular complications will be inevitable worldwide. Although diabetic nephropathy and retinopathy are clearly associated with the duration of diabetes and glycemic control ([@B4]), some patients develop severe complications despite well-controlled blood glucose. Conversely, not all diabetic patients with poor glycemic control develop advanced renal or retinal complications. The underlying mechanism of how these diabetic microvascular complications occur remains largely unknown, but family studies in Pima Indian and European descent populations suggest genetic factors participate in the development of these complications ([@B5]--[@B7]). However, the advance of susceptible gene identification in diabetic microvascular complications was much more limited than it was in type 1 and type 2 diabetes. Recently, a genome-wide association study using Genetics of Kidneys in Diabetes (GoKinD) samples identified four loci associated with diabetic nephropathy in the type 1 diabetic patients of European descent ([@B8]). Maeda et al. ([@B9]) further replicated the effect of one of them (rs1411766 near *IRS2*) in the Japanese type 2 diabetic patients. However, although diabetic retinopathy and nephropathy are two diseases with a high concordance rate in diabetic patients and might share common pathogenesis, no study reported if these single nucleotide polymorphisms (SNPs) had effects on diabetic retinopathy after stratification of the status of diabetic nephropathy. In this study, we aimed to test the effects of SNPs from these four loci on the diabetic nephropathy and retinopathy in Chinese type 2 diabetic patients.

RESEARCH DESIGN AND METHODS {#s5}
===========================

We used a two-stage approach for this study. In stage 1, we recruited 1,276 type 2 diabetic patients from the Shanghai Diabetes Institute Inpatient Database of Shanghai Jiao Tong University Affiliated Sixth People's Hospital ([@B10],[@B11]) and examined them for diabetic retinopathy and nephropathy. These patients included 378 individuals with diabetic nephropathy but no retinopathy, 374 with diabetic retinopathy but no nephropathy, 244 with both diabetic retinopathy and nephropathy, and 280 control subjects. The control subjects were defined as having normoalbuminuria, no retinopathy, and having diabetes for \>10 years. In stage 2, we recruited 590 type 2 diabetic patients from the Shanghai Diabetic Complications Study ([@B12]) and Shanghai Diabetes Institute Inpatient Database, including 209 patients with diabetic retinopathy and 381 patients with diabetes for \>5 years and without retinopathy. The basic characteristics of the study population were shown in [Table 1](#T1){ref-type="table"}.

###### 

Clinical characteristic of the participants

                                         Stage 1                   Stage 2                                                                                               
  -------------------------------------- ------------------------- ------------------------ ------------------------- ------------------------ ------------------------- ------------------------
  Male/female                            102/178                   213/165                  157/217                   135/109                  170/211                   99/110
  Age (years)                            67.04 ± 9.49              61.21 ± 13.74            61.24 ± 10.74             64.36 ± 10.56            64.60 ± 10.35             62.06 ± 11.81
  BMI (kg/m^2^)                          23.85 ± 3.16              25.28 ± 3.77             23.97 ± 3.45              24.43 ± 3.95             24.72 ± 3.49              25.03 ± 3.39
  Age at diagnosis of diabetes (years)   52.88 ± 9.77              54.79 ± 12.67            51.76 ± 10.17             51.70 ± 11.38            53.97 ± 10.50             51.57 ± 11.93
  Duration of diabetes (years)           12.00 (10.00--16.00)      6.00 (0.80--10.00)       10.00 (5.00--14.00)       12.00 (8.00--18.00)      9.00 (6.90--13.00)        10.00 (5.00--15.00)
  Hemoglobin A~1c~ (%)                   8.47 ± 1.99               9.26 ± 2.34              8.98 ± 2.11               9.49 ± 2.21              7.88 ± 1.72               8.96 ± 2.53
  Systolic blood pressure (mmHg)         133.90 ± 17.04            137.62 ± 18.58           135.27 ± 17.92            143.79 ± 19.73           133.42 ± 16.69            134.25 ± 20.98
  Diastolic blood pressure (mmHg)        78.45 ± 8.68              82.23 ± 10.07            80.20 ± 9.37              82.98 ± 9.62             81.12 ± 9.22              80.66 ± 11.56
  AERs (mg/24 h)                         8.81 (6.00--13.44)        79.90 (44.03--203.60)    10.85 (7.17--16.28)       163.62 (54.31--607.54)   10.16 (5.87--29.77)       11.67 (6.18--43.53)
  eGFR[\*](#t1n1){ref-type="table-fn"}   116.82 (102.05--137.85)   112.52 (87.24--138.57)   124.08 (105.21--149.32)   104.72 (76.85--134.74)   124.52 (106.74--145.06)   122.41 (97.73--146.77)

Data are *n*, means ± SD, or medians (interquartile range). eGFR, estimated glomerular filtration rate.

\*eGFR was calculated by using the formula developed by the Modification of Diet in Renal Disease study group with adjustment for the Chinese ethnicity.

This study was approved by the institutional review board of Shanghai Jiao Tong University Affiliated Sixth People's Hospital and in accordance with the principle of the Helsinki Declaration II. Written informed consent was obtained from each participant.

Nephropathy measurement. {#s6}
------------------------

The 24-h albumin excretion rates (AERs) were measured in 3 consecutive days, and the mean value was recorded for each patient. Patients with AER \<30 mg/24 h, 30 mg/24 h ≤ AER \<300 mg/24 h, or AER ≥300 mg/24 h were classified as having normoalbuminuria, microalbuminuria, or proteinuria, respectively. Estimated glomerular filtration rate was calculated by using a formula developed by the Modification of Diet in Renal Disease study group with adjustment for Chinese ethnicity: 186 × (serum creatinine in μmol/L × 0.011)^--1.154^ × (age in years)^--0.203^ × (0.742 if female) × (1.233 if Chinese) ([@B13]).

Retinal assessment. {#s7}
-------------------

Fundus photography was performed following a standardized protocol at the Department of Ophthalmology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital. Both eyes of each participant were photographed with a 45-degree 6.3-megapixel digital nonmydriatic camera (Canon CR6-45NM, Lake Success, NY). Level of retinopathy was defined according to the International Classification of Diabetic Retinopathy ([@B14]): mild nonproliferative diabetic retinopathy, moderate nonproliferative diabetic retinopathy, severe nonproliferative diabetic retinopathy, or proliferative diabetic retinopathy. The worse eye was recorded for each patient.

SNP selection and genotyping. {#s8}
-----------------------------

In stage 1, we genotyped 55 tagging SNPs that capture 95% of the common variants, including one reported SNP from each locus (*CPVL/CHN2* rs39059, *FRMD3* rs10868025, *CARS* rs451041, and *IRS2* rs1411766). The SNPs showed associations to diabetic nephropathy or retinopathy and were genotyped in stage 2 samples. The genotyping was performed by using primer extension of multiplex products with detection by matrix-assisted laser desorption ionization -- time of flight mass spectroscopy using a MassARRAY Compact Analyzer (Sequenom, San Diego, CA).

Statistical analysis. {#s9}
---------------------

The Hardy-Weinberg equilibrium test was performed before the association analysis. The allelic frequencies between the diabetic patients with or without complications were compared by χ^2^ tests using PLINK (v1.07) ([@B15]), and odd ratios (ORs) with 95% CIs were presented. Combined ORs from different studies were calculated by using a Comprehensive Meta Analysis (v2.2.057) with a fixed- or random-effect model after testing for heterogeneity. The test for homogeneity was assessed by the Cochran *Q* test. The genotype-disease association analyses were performed under the additive model by logistic regression with adjustment of confounding factors. The effects of SNPs on the levels of retinopathy severity were analyzed by trend analysis. Skewly distributed quantitative traits (estimated glomerular filtration rate and AER) were logarithmically transformed to approximate univariate normality before analysis. Quantitative traits were analyzed by linear regression with adjustment of confounding factors under an additive genetic model. The statistical analyses were performed using SAS for Windows (version 8.0; SAS Institute, Cary, NC) unless specified otherwise. A two-tailed *P* value of \<0.05 was considered statistically significant.

On the basis of the previously reported effect size of these loci (∼1.40) ([@B8]), our stage 1 samples (∼600 case subjects vs. 600 control subjects) had \>90% power to replicate the reported effects of SNPs with minor allele frequencies \>0.2 and 75% power to replicate the effect SNP with minor allele frequency of 0.1 at a level of significance of 0.05.

RESULTS {#s10}
=======

We firstly analyzed the effects of these SNPs on diabetic retinopathy and nephropathy in stage 1 samples ([Supplementary Tables 1 and 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0028/-/DC1)). As shown in [Table 2](#T2){ref-type="table"}, four *CPVL/CHN2* SNPs (rs39059, rs17756941, rs245955, and rs245962) and *FRDM3* rs10868025 were nominally associated with diabetic retinopathy (*P* \< 0.05), with rs39059 and rs10868025 showing the strongest association within each locus (OR 0.774, 95% CI 0.657--0.912, *P* = 0.002, for rs39059 G allele; 0.833, 0.703--0.987, *P* = 0.034, for rs10868025 G allele). However, none of the genotyped SNPs showed a significant association to diabetic nephropathy.

###### 

Effects of the SNPs on diabetic retinopathy and nephropathy in stage 1 samples

  Chromosome   SNP          Position    Minor/major allele   Diabetic retinopathy   Diabetic nephropathy                          
  ------------ ------------ ----------- -------------------- ---------------------- ---------------------- ---------------------- -------
  7            rs3812398    29237994    C,T                  0.970 (0.816--1.153)   0.728                  1.087 (0.915--1.292)   0.341
  7            rs3812389    29244759    A,G                  0.839 (0.679--1.036)   0.103                  0.960 (0.778--1.185)   0.704
  7            rs2269903    29247409    C,A                  1.202 (0.976--1.481)   0.084                  1.026 (0.832--1.264)   0.813
  7            rs3812388    29249198    G,C                  1.190 (0.967--1.464)   0.100                  1.055 (0.858--1.298)   0.611
  7            rs17756941   29250007    G,A                  0.747 (0.598--0.933)   **0.010**              0.941 (0.755--1.174)   0.593
  7            rs11981737   29250335    A,G                  1.064 (0.736--1.536)   0.743                  0.834 (0.578--1.204)   0.334
  7            rs39059      29255470    G,A                  0.774 (0.657--0.912)   **0.002**              0.959 (0.814--1.131)   0.621
  7            rs39065      29262601    A,G                  0.973 (0.711--1.331)   0.862                  1.180 (0.862--1.614)   0.300
  7            rs17157658   29274254    C,G                  0.858 (0.719--1.024)   0.090                  1.051 (0.881--1.254)   0.577
  7            rs245955     29276307    C,T                  0.784 (0.668--0.921)   **0.003**              0.989 (0.843--1.161)   0.896
  7            rs245962     29290153    A,G                  0.800 (0.681--0.939)   **0.006**              0.989 (0.842--1.161)   0.893
  7            rs39099      29293095    A,G                  0.910 (0.762--1.085)   0.293                  1.042 (0.874--1.243)   0.646
  7            rs39101      29294462    A,G                  1.049 (0.846--1.301)   0.664                  0.884 (0.712--1.096)   0.261
  9            rs11140139   86145409    A,G                  1.018 (0.848--1.221)   0.854                  1.010 (0.841--1.211)   0.918
  9            rs4877788    86146950    C,T                  1.029 (0.866--1.221)   0.750                  1.044 (0.880--1.240)   0.620
  9            rs7849075    86149610    C,T                  0.972 (0.787--1.199)   0.787                  0.971 (0.787--1.198)   0.783
  9            rs1888746    86155392    T,C                  0.815 (0.538--1.234)   0.334                  0.928 (0.602--1.380)   0.661
  9            rs11140156   86163694    G,C                  0.922 (0.717--1.186)   0.528                  0.919 (0.714--1.183)   0.511
  9            rs10868025   86164176    G,A                  0.833 (0.703--0.987)   **0.034**              0.905 (0.764--1.072)   0.249
  9            rs11535575   86165034    T,C                  0.671 (0.439--1.025)   0.065                  0.762 (0.501--1.160)   0.205
  9            rs6559732    86168692    C,T                  1.152 (0.948--1.399)   0.154                  1.080 (0.889--1.311)   0.440
  9            rs7470287    86172665    C,G                  0.840 (0.687--1.027)   0.090                  0.963 (0.788--1.177)   0.712
  9            rs3934902    86177401    A,G                  1.103 (0.938--1.298)   0.237                  1.018 (0.865--1.197)   0.835
  9            rs4451390    86179563    T,C                  1.000 (0.848--1.180)   0.998                  1.042 (0.883--1.229)   0.628
  9            rs11793821   86184504    G,A                  1.116 (0.861--1.447)   0.407                  0.915 (0.706--1.187)   0.503
  11           rs3764895    2945945     T,C                  0.994 (0.802--1.231)   0.954                  0.897 (0.724--1.112)   0.321
  11           rs2583442    2956166     A,G                  1.021 (0.860--1.211)   0.812                  0.993 (0.837--1.179)   0.940
  11           rs4758576    2973880     G,A                  0.956 (0.726--1.259)   0.751                  0.912 (0.692--1.201)   0.512
  11           rs11024758   2981782     T,C                  1.180 (0.640--2.174)   0.596                  1.590 (0.853--2.962)   0.144
  11           rs4758504    3000179     A,G                  0.963 (0.724--1.279)   0.794                  0.901 (0.678--1.198)   0.473
  11           rs4758621    3009640     A,G                  1.008 (0.851--1.194)   0.925                  0.990 (0.836--1.173)   0.911
  11           rs12363575   3030104     G,A                  1.007 (0.783--1.294)   0.958                  1.104 (0.859--1.420)   0.438
  11           rs12421922   3035070     T,C                  1.024 (0.868--1.209)   0.778                  0.996 (0.844--1.175)   0.961
  11           rs2071101    3050137     A,G                  1.042 (0.885--1.225)   0.624                  0.939 (0.798--1.105)   0.451
  11           rs572373     3055361     C,T                  1.061 (0.878--1.281)   0.541                  1.032 (0.854--1.247)   0.745
  11           rs451041     3060725     A,G                  1.046 (0.881--1.243)   0.605                  1.010 (0.851--1.200)   0.906
  11           rs7111857    3068106     A,G                  1.069 (0.876--1.306)   0.511                  1.044 (0.855--1.274)   0.676
  11           rs6578318    3072442     T,C                  1.009 (0.792--1.284)   0.945                  0.981 (0.770--1.248)   0.873
  11           rs2290000    3073838     T,A                  1.019 (0.801--1.296)   0.878                  0.969 (0.762--1.233)   0.799
  11           rs406598     3076285     C,T                  1.016 (0.859--1.203)   0.850                  1.002 (0.847--1.185)   0.980
  11           rs10833173   3094505     A,T                  1.033 (0.837--1.275)   0.760                  0.950 (0.770--1.173)   0.635
  11           rs2084239    3106659     G,A                  0.983 (0.831--1.163)   0.845                  0.958 (0.810--1.133)   0.617
  13           rs914270     110243017   C,G                  0.995 (0.847--1.169)   0.954                  0.955 (0.812--1.122)   0.573
  13           rs2391776    110243425   C,T                  0.937 (0.735--1.194)   0.599                  1.006 (0.790--1.281)   0.963
  13           rs1041466    110244322   C,T                  1.264 (0.945--1.691)   0.115                  0.782 (0.584--1.048)   0.100
  13           rs11069790   110244401   A,G                  0.937 (0.784--1.121)   0.477                  1.102 (0.921--1.317)   0.288
  13           rs4462453    110251328   G,A                  1.246 (0.902--1.719)   0.182                  0.869 (0.629--1.199)   0.392
  13           rs1411766    110252160   T,C                  1.094 (0.828--1.445)   0.530                  0.991 (0.750--1.310)   0.951
  13           rs12184748   110253930   C,T                  1.001 (0.845--1.186)   0.990                  1.028 (0.868--1.217)   0.754
  13           rs2150481    110256550   G,C                  1.079 (0.917--1.269)   0.362                  1.030 (0.876--1.212)   0.717
  13           rs2391778    110258553   T,A                  1.048 (0.888--1.236)   0.582                  1.037 (0.879--1.223)   0.666
  13           rs1547241    110273605   G,C                  1.108 (0.824--1.490)   0.497                  0.858 (0.637--1.155)   0.311
  13           rs10161791   110281789   G,A                  0.938 (0.786--1.121)   0.483                  1.106 (0.926--1.321)   0.264
  13           rs9587939    110284951   A,C                  0.965 (0.810--1.150)   0.693                  1.055 (0.885--1.257)   0.549
  13           rs4773068    110288967   A,G                  0.924 (0.771--1.107)   0.390                  1.160 (0.968--1.390)   0.108

*P* values \<0.05 are shown in boldface. ORs with 95% CIs were calculated for the minor allele.

To further validate the effects of rs39059 and rs10868025 on diabetic retinopathy, we genotyped both SNPs in stage 2 samples. We found only *CPVL/CHN2* rs39059 showed similar effects to diabetic retinopathy, as identified in the first stage (OR 1.269, 95% CI 0.989--1.628, *P* = 0.061, for rs39059; 1.014, 0.789--1.302, *P* = 0.9147, for rs10868025). We then performed a meta-analysis with the fixed-effect model and found rs39059 was associated with diabetic retinopathy, with an OR of 1.285 (1.120--1.474, *P* = 0.0003) ([Table 3](#T3){ref-type="table"}). This association remained significant after adjusting confounding factors, including hemoglobin A~1c~ levels, duration of diabetes, systolic and diastolic blood pressure, and BMI (OR 1.242, 1.074--1.437, *P* = 0.0034).

###### 

Association of rs39059 in *CPVL/CHN2* with diabetic retinopathy in Chinese type 2 diabetic patients

                                                                  *n* (case/control)   Risk allele frequencies   OR (95% CI)[\*](#t3n1){ref-type="table-fn"}   *P*                    
  --------------------------------------------------------------- -------------------- ------------------------- --------------------------------------------- ---------------------- ---------------------------------------
  Diabetic retinopathy vs. control subjects                       365/273              0.619                     0.564                                         1.256 (1.003--1.575)   0.047
  Diabetic nephropathy and retinopathy vs. diabetic nephropathy   231/363              0.636                     0.567                                         1.334 (1.049--1.695)   0.018
  Stage 2 validation                                              209/381              0.660                     0.605                                         1.269 (0.989--1.628)   0.061
  Meta-analysis                                                   805/1,017            0.633                     0.581                                         1.285 (1.120--1.474)   0.0003[†](#t3n2){ref-type="table-fn"}

\*ORs with 95% CIs were shown for risk allele.

†*P* values of meta*-*analysis were calculated using the fixed-effect model; homogeneity test *P* = 0.932.

We then analyzed the effects of *CPVL/CHN2* rs39059 on the disease severity of diabetic retinopathy in all the samples. As shown in [Fig. 1](#F1){ref-type="fig"}, *CPVL/CHN2* rs39059 showed an association to the levels of diabetic retinopathy, with the risk allele more frequent in the more severe retinopathy patients (*P* = 0.0007 for trend analysis).

![The effects of *CPVL/CHN2* rs39059 on the disease severity of diabetic retinopathy. Numbers within the bar represent the number of participants of each group. NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.](3085fig1){#F1}

DISCUSSION {#s11}
==========

In the current study, we analyzed the effects of SNPs from four loci on diabetic retinopathy and nephropathy in Chinese type 2 diabetic patients. We first reported that *CPVL/CHN2* rs39059 was associated with diabetic retinopathy. Although the association we observed was solid by replication in independent samples and the *P* value remained significant after Bonferroni correction of analysis on multiple SNPs (corrected *P* = 0.033, on the basis of the association analysis between 55 SNPs and two traits), we still cannot fully exclude the possibility that the association detected was false positive because of the relatively small sample size of this study. But considering we also found an association between rs39059 and disease severity in our samples, which supported the role of this locus in diabetic retinopathy from another aspect, the chance of a false-positive finding was limited. Although this locus was originally identified to be associated with diabetic nephropathy in a previous genome-wide association study (since the concordance rate of retinopathy and nephropathy was high in diabetic patients \[[@B16]\] and the genome-wide association study in the GoKinD samples ([@B8]) did not exclude the patients with retinopathy), *CPVL/CHN2* may be a susceptible locus of diabetic retinopathy other than nephropathy. However, whether this effect is restricted to type 2 diabetes is still unknown and needs to be investigated in studies with type 1 diabetic patients.

The SNP rs39059 locates in the intron of *CHN2*, which encodes β-2 chimerin that have been shown to regulate cell growth, proliferation, and migration ([@B17]). Previous studies showed decreased expression of *CHN2* is associated with high-grade malignant gliomas, breast cancer, and duodenal adenocarcinoma, whereas increased expression of *CHN2* is reported to be associated with lymphomas ([@B17],[@B18]). One other gene within the same haplotype block of rs39059 is *CPVL*. It encodes a carboxypeptidase that cleaves a single amino acid from the COOH termini of peptides ([@B19]). However, the function of this gene is still largely unknown. Although hemoglobin A~1c~ levels and systolic blood pressure were also associated with diabetic retinopathy in our samples (*P* = 0.0065 for systolic blood pressure and *P* = 7.0 × 10^−9^ for hemoglobin A~1c~), since rs39059 showed association to none of these traits (*P* = 0.5031 for systolic blood pressure and *P* = 0.1561 for hemoglobin A~1c~), our data suggest this locus did not participate in the pathogenesis of diabetic retinopathy through the effects on blood pressure and glucose levels. Thus, the mechanism how this locus affected diabetic retinopathy susceptibility remains to be investigated. And the causal variant also remains to be identified by fine mapping studies.

In this study, we failed to replicate the associations between these four loci and diabetic nephropathy in Chinese type 2 diabetic patients, although we had enough statistical power. Because we used a tagging SNP approach and captured most of the common variants within these loci, it was unlikely that causal variants were captured by different SNPs in different populations. One possible explanation may be the complicated phenotypes in type 2 diabetic patients. In our study, \>60% of the diabetic nephropathy patients also suffered from hypertension; although we statistically adjusted blood pressure as a confounding factor, the impact of hypertension cannot be ignored. In a previous replication study in Japanese type 2 diabetic patients, Maeda et al. ([@B9]) also failed to replicate the effects of most of these loci in four independent samples; thus, it is highly possible that the effects of these loci on diabetic nephropathy are restricted in the European descent population or type 1 diabetic patients. Further studies with type 1 diabetic patients are needed to confirm the effects of these loci.

In summary, we found *CPVL/CHN2* rs39059 was associated with diabetic retinopathy in Chinese type 2 diabetic patients. Further studies are needed to replicate this finding.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0028/-/DC1>.
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